reports
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding L...
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- (Nas...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted sto...
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Glo...
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The presentation will be available through an on-demand webcast beginning at 7 a.m. ET on September 13, 2021, and will be accessible on the Flexion website at . Ab...
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Health...
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021. To access the live webcast of the presentation, please visit the Flexion website at . About Flexion TherapeuticsFlexion Therapeut...
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Acad...
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its...
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigati...
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain Initial findings from proof-of-concept trial in patients undergoing bunionectomy support expansion of the study to include 36 additional patientsData from the trial, including the expansion cohort, anticipated by year-end BURLINGTON, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a n...
Flexion Therapeutics Announces Publication of Results from Phase 2 Pha...
Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA) Data published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA Plasma PK data indicate the total and maximal exposure to triamcinolone acetonide (TA) was approximately two-thirds lower in patients treated with ZILRETTA compared to triamcinolone acetonide in crystalline suspension (TAcs)Registration trial in patients with shoulder OA ...
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and...
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarterNet loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA salesCompany extends estimated cash runway into 2023 by refinancing term loanFlexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 millionData for FX301 buni...
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results o...
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021 BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET. A live webcast of the conference call can be accessed through the “” tab on the Flexion Therapeutics website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference c...
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Bo...
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion’s audit committee. "I am thrilled to welcome Utpal to Flexion’s Board, as his extensive financial experience leading biotechnology companies makes him an outstanding addition to our Board of Directors,” said Michael Clayman, MD, Presiden...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURLINGTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of July 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock ...
Flexion Therapeutics to Present at the 2021 Raymond James Human Health...
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference. The virtual fireside chat is scheduled to begin at 3:20 p.m. ET on Monday, June 21, 2021. To access the live webcast of the presentation, please visit the Flexion website at . About Flexion TherapeuticsFlexion Th...
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D....
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impressive combination of medical, clinical, regulatory and corporate development skills, complemented by deep commercial experience he gained launching seven products throughout his career,” said Michael Clayman, MD, President and Chief Exe...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of June 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock u...
Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Globa...
Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference. The virtual fireside chat is scheduled to begin at 3:50 p.m. ET on Tuesday, June 8, 2021. To access the live webcast and subsequent archived recording of the presentation, please visit the Flex...
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtua...
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference. The virtual fireside chat is scheduled to begin at 1:55 p.m. ET on Wednesday, May 19, 2021. To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion...
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and ...
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates Flexion reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $24.6 millionDavid Arkowitz, CFO, stepping down effective May 31,2021, and will be succeeded by Fred DriscollNew data presented at ASGCT indicate the low dose of FX201 provided durable pain improvement for two patients with knee OA out to Week 52Conference call scheduled for today at 4:30 p.m. ET BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) toda...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURLINGTON, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of May 3, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock u...
Flexion Therapeutics to Report First-Quarter 2021 Financial Results on...
Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021 BURLINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, May 12, 2021. A live webcast of the conference call can be accessed through the “” tab on the Flexion Therapeutics website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is 855-770-0022 for d...
Flexion Therapeutics Announces Presentation of Preliminary FX201 Clini...
Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Findings from a Phase 1 single ascending dose trial indicate the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis (OA), was generally well-toleratedTwo of five patients (40%) treated with FX201 in the low-dose, single ascending dose cohort reported substantial improvement in pain out to Week 24No evidence of systemic biodistribution of FX201 in plasma or shedding in urine or at the injection site was...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.